FDA approves first drug for serious liver disease

The U.S. Food and Drug Administration approved the first drug to treat moderate to serious liver disease. Rezdiffra is now permitted to treat livers that develop scar tissue due to a form of liver inflammation called nonalcoholic steatohepatitis, or NASH. 

NASH results from nonalcoholic fatty liver disease progressing from liver inflammation into scarring and potential dysfunction, according to the FDA, and is often associated with other health problems like high blood pressure and type 2 diabetes. 

"Previously, patients with NASH who also have notable liver scarring did not have a medication that could directly address their liver damage. Today's approval of Rezdiffa will, for the first time, provide a treatment option for these patients, in addition to diet and exercise," said Nikolay Nikolov, M.D., the acting director of the FDA's Office of Immunology and Inflammation. 

Read more: FDA

The article presented here is intended to inform you about the broader media perspective on dentistry, regardless of its alignment with the ADA's stance. It is important to note that publication of an article does not imply the ADA's endorsement, agreement, or promotion of its content.